Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Desmoplastic small round cell tumor

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44351   clinical trials with a EudraCT protocol, of which   7378   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    18 result(s) found for: Desmoplastic small round cell tumor. Displaying page 1 of 1.
    EudraCT Number: 2018-004242-42 Sponsor Protocol Number: J1S-MC-JV01 Start Date*: 2021-05-12
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized, Open-Label Phase 2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults with Relapsed, Recurrent, or Refractory Desmoplastic Small Round Cell Tumor.
    Medical condition: Desmoplastic small round cell tumour (DSRCT)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10064581 Desmoplastic small round cell tumour PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) ES (Ongoing) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-002464-14 Sponsor Protocol Number: GEIS-39 Start Date*: 2017-03-02
    Sponsor Name:Grupo Español de Investigación en Sarcomas (GEIS)
    Full Title: Phase II trial of nab-paclitaxel for the treatment of desmoid tumors and multiply relapsed/refractory desmoplastic small round cell tumors and Ewing sarcoma
    Medical condition: Cohort 1: Subjects with desmoid tumor Cohort 2: Subjects with desmoplastic small round cell tumor or Ewing sarcoma
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-001614-41 Sponsor Protocol Number: CSTI571BIT06 Start Date*: 2005-05-19
    Sponsor Name:NOVARTIS FARMA
    Full Title: OPEN-LABEL TRIAL OF GLIVEC IMATINIB MESYLATE IN PATIENTS WITH REFRACTORY DESMOPLASTIC SMALL ROUND CELL TUMORS DSRCT EXPRESSING A MOLECULAR TARGET OF GLIVEC PDGF-R AND/OR C-KIT
    Medical condition: TREATMENT OF PATIENTS WITH REFRACTORY DESMOPLASTIC SMALL ROUND CELL TUMORS DSRCT .
    Disease: Version SOC Term Classification Code Term Level
    6.1 10039491 PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-003940-30 Sponsor Protocol Number: NO21157 Start Date*: 2008-05-14
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A Phase II Trial of R1507, a Recombinant Human Monoclonal Antibody to the Insulin-Like Growth Factor-1 Receptor for the treatment of patients with recurrent or refractory Ewing’s sarcoma, osteosarc...
    Medical condition: Ewing’s sarcoma and other sarcoma subtypes
    Disease: Version SOC Term Classification Code Term Level
    9.1 10015560 Ewing's sarcoma LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) FR (Completed) ES (Completed) SE (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2004-001108-11 Sponsor Protocol Number: EORTC protocol 62033 Start Date*: 2004-11-08
    Sponsor Name:European Organisation for the Research and Treatment of Cancer
    Full Title: A phase II study of intravenous TZT-1027, administered weekly times two, every three weeks, to patients with advanced or metastatic soft tissue sarcomas (STS) with prior exposure to doxorubicin-bas...
    Medical condition: Soft Tissue Sarcoma (STS) is a rare group of heterogeneous mesenchymal cancers originating from connective tissue. There are multiple histological subtypes of STS. At present all these subtypes are...
    Disease: Version SOC Term Classification Code Term Level
    7.0 10041299 HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-002821-28 Sponsor Protocol Number: ET20-128 Start Date*: 2020-12-24
    Sponsor Name:Centre Léon Bérard
    Full Title: RAR-Immune: A randomised, comparative, prospective, multicentre study of the efficacy of nivolumab + ipilimumab versus pazopanib alone in patients with metastatic or unresectable advanced sarcoma o...
    Medical condition: Metastatic or unresectable advanced rare sarcomas
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-005017-19 Sponsor Protocol Number: BO20924 Start Date*: 2008-06-17
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: Open-label, multi-center, randomized, phase II study evaluating the addition of bevacizumab to chemotherapy in childhood and adolescent patients presenting with metastatic rhabdomyosarcoma and non-...
    Medical condition: Patients aged 6 months to <18 years, presenting with metastatic rhabdomyosarcoma and non-rhabdomyosarcoma soft tissue sarcoma.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061526 Malignant mesenchymoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065868 Embryonal rhabdomyosarcoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065867 Alveolar rhabdomyosarcoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10058387 Schwannoma malignant LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10039024 Rhabdomyosarcoma NOS LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10039494 Sarcoma NOS LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10039022 Rhabdomyosarcoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10039026 Rhabdomyosarcoma previously untreated LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10024189 Leiomyosarcoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10042864 Synovial sarcoma metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029274 Neurofibrosarcoma metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016635 Fibrosarcoma metastatic PT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060651 Malignant hemangiopericytoma metastatic LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10024629 Liposarcoma metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001882 Alveolar soft part sarcoma PT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10064581 Desmoplastic small round cell tumour PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016632 Fibrosarcoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015099 Epithelioid sarcoma PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) FR (Completed) NL (Completed) IT (Completed) BE (Completed) ES (Completed) PL (Completed) DE (Completed) CZ (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2013-003595-12 Sponsor Protocol Number: ADVL1322-VEG116731 Start Date*: 2013-09-04
    Sponsor Name:GlaxoSmithKline
    Full Title: A Phase II Study of Pazopanib in Children, Adolescents and Young Adults with Refractory Solid Tumors.
    Medical condition: relapsed solid tumours in children, adolescents and young adults.
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA CZ (Completed) SK (Completed) ES (Completed) HU (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2006-001861-40 Sponsor Protocol Number: BRTA-0100-015 (EORTC 62061) Start Date*: 2006-09-21
    Sponsor Name:SYSTEMS MEDICINE, LLC
    Full Title: Randomized phase II study of brostallicin (PNU-166196A) versus doxorubicin as first line chemotherapy in patients with advanced or metastatic soft tissue sarcoma
    Medical condition: Advanced or metastatic soft tissue sarcoma.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10041299 Soft tissue sarcomas HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) GB (Completed) NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-004272-20 Sponsor Protocol Number: E7389-E044-207 Start Date*: 2006-10-23
    Sponsor Name:Eisai Limited
    Full Title: Phase II Study of E7389 Administered as an IV Infusion Day 1 and 8 every 3 Weeks in Pretreated Patients with Advanced and/or Metastatic Soft Tissue Sarcoma Protocol Version 5.0 (2010-01-27)
    Medical condition: Advanced and/or metastatic soft tissue sarcoma
    Disease: Version SOC Term Classification Code Term Level
    8.1 10041299 Soft tissue sarcomas HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) DK (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2008-002326-11 Sponsor Protocol Number: ET-C-002-07 Start Date*: 2008-10-22
    Sponsor Name:Pharma Mar, S.A.
    Full Title: A Randomized, Multicenter, Phase III Trial of Trabectedin (Yondelis®) versus Doxorubicin-based Chemotherapy as First-Line Therapy in Patients with Translocation-Related Sarcomas (TRS)
    Medical condition: Translocation-Related Sarcomas
    Disease: Version SOC Term Classification Code Term Level
    9.1 10041299 Soft tissue sarcomas HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) ES (Prematurely Ended) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-004486-17 Sponsor Protocol Number: A4021020 Start Date*: 2008-08-26
    Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017
    Full Title: A PHASE 1/PHASE 2 STUDY OF CP-751,871 IN PATIENTS WITH RELAPSED AND/OR REFRACTORY EWING’S SARCOMA FAMILY OF TUMORS
    Medical condition: Ewing's sarcoma family tumours
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015562 Ewing's sarcoma metastatic PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) NL (Not Authorised) ES (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-005858-21 Sponsor Protocol Number: WWU190007 Start Date*: 2021-09-17
    Sponsor Name:Universität Münster c/o Universitätsklinikum Münster, Geschäftsbereich Recht u. Drittmittel
    Full Title: PHASE III STUDY COMPARING TRABECTEDIN (T) VERSUS T PLUS tTF-NGR TO ENTRAP T INSIDE THE TUMOR IN PATIENTS WITH METASTATIC AND/OR REFRACTORY SOFT TISSUE SARCOMA (STS)
    Medical condition: Patients (18-75 years) with metastatic and/or refractory soft-tissue sarcoma after failure of anthracycline-containing 1st line therapy or with contraindications to anthracyclines (CD13 positivity:...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073135 Dedifferentiated liposarcoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10024628 Liposarcomas malignant HLT
    27.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10024629 Liposarcoma metastatic PT
    27.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10024630 Liposarcoma non-metastatic LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10024627 Liposarcoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10024632 Liposarcoma recurrent PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10024631 Liposarcoma NOS LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10024633 Liposarcoma stage unspecified LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073136 Mixed-type liposarcoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073137 Myxoid liposarcoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073138 Pleomorphic liposarcoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073139 Round cell liposarcoma PT
    27.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077843 Myxoid liposarcoma metastatic LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016634 Fibrosarcomas malignant HLT
    27.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016635 Fibrosarcoma metastatic PT
    27.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016636 Fibrosarcoma non-metastatic LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016632 Fibrosarcoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016637 Fibrosarcoma NOS LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016638 Fibrosarcoma stage unspecified LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066948 Myxofibrosarcoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10024190 Leiomyosarcomas HLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041127 Small intestine leiomyosarcoma PT
    27.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10024191 Leiomyosarcoma metastatic PT
    27.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10024192 Leiomyosarcoma non-metastatic LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10024189 Leiomyosarcoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10024194 Leiomyosarcoma recurrent PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10046799 Uterine leiomyosarcoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057340 Testicular leiomyosarcoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10024193 Leiomyosarcoma NOS LLT
    22.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10082419 Pleomorphic leiomyosarcoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10039023 Rhabdomyosarcomas HLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10039022 Rhabdomyosarcoma PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10039027 Rhabdomyosarcoma recurrent PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10039024 Rhabdomyosarcoma NOS LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10039026 Rhabdomyosarcoma previously untreated LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10039025 Rhabdomyosarcoma previously treated LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065867 Alveolar rhabdomyosarcoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025224 Lymphangiosarcomas HLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025223 Lymphangiosarcoma PT
    27.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10002477 Angiosarcoma metastatic PT
    27.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057700 Angiosarcoma non-metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10002476 Angiosarcoma PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10002480 Angiosarcoma recurrent PT
    27.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10002478 Angiosarcoma nonmetastatic LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10002479 Angiosarcoma NOS LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018828 Haemangiosarcoma NOS LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025225 Lymphangiosarcoma NOS LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10002481 Angiosarcoma stage unspecified LLT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10019407 Hemangiosarcoma LLT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018827 Haemangiosarcoma LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067388 Hepatic angiosarcoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10072813 Breast angiosarcoma PT
    27.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10072814 Breast angiosarcoma metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10072891 Skin angiosarcoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077861 Cholangiosarcoma PT
    27.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10042864 Synovial sarcoma metastatic PT
    27.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10042865 Synovial sarcoma non-metastatic LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10042863 Synovial sarcoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10042867 Synovial sarcoma recurrent PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10042866 Synovial sarcoma NOS LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10045515 Undifferentiated sarcoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) AT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-004168-30 Sponsor Protocol Number: STS001 Start Date*: 2012-08-07
    Sponsor Name:Hannover Medical School
    Full Title: A randomized phase II trial comparing pazopanib with doxorubicin as first line treatment in elderly patients with metastatic or advanced soft tissue sarcoma
    Medical condition: Metastatic or advanced soft tissue sarcoma
    Disease: Version SOC Term Classification Code Term Level
    15.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041299 Soft tissue sarcomas HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2016-003239-38 Sponsor Protocol Number: PH-L19TNFDOX2-03/16 Start Date*: 2017-07-28
    Sponsor Name:Philogen S.p.A.
    Full Title: A Phase III study comparing the efficacy of the combination of doxorubicin and the tumor-targeting human antibody-cytokine fusion protein L19TNF to doxorubicin alone as first-line therapy in patien...
    Medical condition: Unresectable or metastatic soft tissue sarcoma
    Disease: Version SOC Term Classification Code Term Level
    15.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041299 Soft tissue sarcomas HLGT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075333 Soft tissue sarcoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) IT (Trial now transitioned) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-004750-15 Sponsor Protocol Number: AIO-STS-0415 Start Date*: 2017-10-06
    Sponsor Name:AIO-Studien-gGmbH
    Full Title: A randomized phase II study of Durvalumab (MEDI4736) and Tremelimumab compared to doxorubicin in patients with advanced or metastatic soft tissue sarcoma.
    Medical condition: advanced or metastatic soft tissue sarcoma
    Disease: Version SOC Term Classification Code Term Level
    15.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041299 Soft tissue sarcomas HLGT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075333 Soft tissue sarcoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-001029-32 Sponsor Protocol Number: PBI-200-101 Start Date*: 2022-01-18
    Sponsor Name:Pyramid Biosciences, Inc.
    Full Title: A Phase 1/2 Study of PBI-200 in Subjects with NTRK-Fusion-Positive Advanced or Metastatic Solid Tumors
    Medical condition: One of the following solid tumors which has progressed on or following at least one systemic therapy regimen administered for advanced or metastatic disease or for which no approved therapy exists:...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-003745-18 Sponsor Protocol Number: GISG-04 Start Date*: 2012-05-22
    Sponsor Name:University of Heidelberg
    Full Title: A PHASE II WINDOW-OF-OPPORTUNITY STUDY OF PREOPERATIVE THERAPY WITH PAZOPANIB (VOTRIENT®) IN HIGH-RISK SOFT TISSUE SARCOMA
    Medical condition: High-risk soft tissue sarcoma
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041298 Soft tissue sarcomas histology unspecified HLT
    15.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041299 Soft tissue sarcomas HLGT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10024628 Liposarcomas malignant HLT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10024190 Leiomyosarcomas HLT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10023285 Kaposi's sarcomas HLT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001883 Alveolar soft part sarcomas HLT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025224 Lymphangiosarcomas HLT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10039023 Rhabdomyosarcomas HLT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016634 Fibrosarcomas malignant HLT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029273 Neurofibrosarcomas HLT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015100 Epithelioid sarcomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jul 20 13:40:10 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA